- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05158673
Effect of Cocoa Polyphenols Supplementation on Cardiovascular Risk of Postmenopausal Women
Effect of Cocoa Polyphenols Supplementation on Cardiovascular Risk of Overweight or Obese Postmenopausal Women: Double Blind Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Some interventions have been carried out to reduce obesity and the incidence of cardio-metabolic pathologies since the foods consumed in the daily diet, directly and indirectly, influence the modulation of metabolic signaling pathways. Flavonoids, nutrients of plant origin, have beneficial effects on health since they can prevent and reduce the impact of overweight/obesity. Significant benefits have also been shown in blood pressure, platelet reactivity, HDL cholesterol, LDL cholesterol, insulin sensitivity, and prostaglandin metabolism, improving health in patients with chronic diseases related to metabolic disorders and OS.
Food rich in flavonoids is cocoa; the plant contains many polyphenols (anthocyanidins, proanthocyanidins, and catechins), concentrated mainly in the pods and seeds, which provides a highly bitter taste. The polyphenols that can be identified in cocoa beans are (-) - epicatechin and, to a lesser extent (+) - catechin, (+) - gallocatechin, and (-) - epigallocatechin.
Polyphenols derived from cocoa are characterized by being powerful antioxidants, by having effects on muscle and fat tissue: inducing the darkening of adipocytes (change from white adipocytes (fat deposit) to beige adipocytes; promoting mitochondrial biogenesis; increasing the expression of vital thermogenic genes and upstream regulators of fatty acid oxidation; reducing serum TG concentrations; phosphorylating metabolism regulators and acetylating (activating) proteins involved in mitochondrial structure and function. Actions culminate in regulating the metabolic profile, decreasing adipose tissue, increasing muscle mass, and, therefore, decreasing BMI.
There is evidence of the beneficial effects of cocoa polyphenols as antioxidants, improving the lipid profile levels and pro and anti-inflammatory markers. Cocoa is one of the foods of natural origin with high antioxidant capacity due to the tricyclic structure of flavonoids. The compounds act as electron donors and stabilize free radicals through their aromatic rings with hydroxyl substituents. Cocoa polyphenols have been shown to protect cells from oxidative stress at the membrane level by reducing lipoperoxidation and DNA damage through the chelating action of the catechol group and hydroxyl substituents. Furthermore, cocoa flavonoids inhibit xanthine oxidase, NADPH-oxidase, tyrosine kinases, and protein kinases.
Cocoa polyphenols have been shown to have antioxidant activity that helps counteract the atherosclerotic process by reducing the activation of NADPH oxidase. In addition, to improve the dilation of the arteries in smoking patients with atherosclerosis. The antioxidants in cocoa inhibit LDL oxidation, which is related to delaying atherosclerotic progression by reducing ox-LDL and increasing HDL-c.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Araceli Montoya-Estrada, PhD
- Phone Number: 307 525555209900
- Email: ara_mones@hotmail.com
Study Contact Backup
- Name: Nayelli Najéra, PhD
- Phone Number: 62820 525557296000
- Email: nnajerag@ipn.mx
Study Locations
-
-
-
Mexico City, Mexico, 11000
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
-
Contact:
- Araceli Montoya-Estrada, PhD
- Phone Number: 307 +52 5555209900
- Email: ara_mones@hotmail.com
-
Sub-Investigator:
- Guillermo Ceballos, PhD
-
Principal Investigator:
- Nayelli Najera, PhD
-
Sub-Investigator:
- Guillermo Ortiz-Luna, MD
-
Sub-Investigator:
- Enrique Reyes-Muñoz, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- -According to the STRAW classification (+ 1A + 1B + 1C), women with an early postmenopause diagnosis attend the INPerIER Peri and Postmenopause Clinic.
- Age between 50 and 60 years.
- who have metabolic syndrome
- Who present an altered lipid and glycemic profile that have not reached the critical point of pharmacological treatment (blood glucose between 100 and 125 mg/dl, cholesterol between 200 and 280 mg/dl, triglycerides between 150 and 300 mg/dl, lower HDL 50 mg/dl).
- That they are not taking metformin
- That they have not taken metformin in the three months before entering the study.
- That they are not taking bezafibrate and/or statins.
- That they have not taken bezafibrate and/or statins in the three months before entering the study.
- No indication for hormone replacement therapy.
- That they sign the informed consent.
Exclusion Criteria:
- Women who present pathologies such as Diabetes Mellitus, rheumatoid arthritis, lupus, neoplasms of any type, HIV, or kidney diseases during the development of the study.
- Women who require hormone replacement therapy during the development of the protocol.
- That the patient has any surgical intervention during the development of the study.
- Women who consume or require the use of lipid-lowering drugs during the development of the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group A (Placebo)
The administration of two capsules of 500 mg orally of placebo (excipient q.s.
starch capsule) 1 every 12 hours, for 12 weeks.
|
Dietary supplement: The administration of two capsules of 500 mg orally of placebo (excipient q.s.
starch capsule) 1 every 12 hours, for 12 weeks
|
Active Comparator: Group B (Flavonoid)
Two capsules of 500 mg of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours for 12 weeks.
|
Dietary supplement: Two 500 mg capsules of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours (one in the morning and one at night) for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Metabolic Syndrome
Time Frame: Metabolic Syndrome at three months after starting the intervention in each group
|
Metabolic syndrome according to International Diabetes Federation Criteria
|
Metabolic Syndrome at three months after starting the intervention in each group
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Carbonylation of proteins
Time Frame: Three months after starting the intervention in each group
|
Marker of oxidative stress measured by spectrophotometry expressed as pmol PC/mg protein
|
Three months after starting the intervention in each group
|
Malondialdehyde
Time Frame: Three months after starting the intervention in each group
|
Marker of oxidative stress measured by spectrophotometry expressed as pmol MDA/mg dry weight
|
Three months after starting the intervention in each group
|
Superoxide Dismutase activity
Time Frame: Three months after starting the intervention in each group
|
Enzymatic activity measured by Colorimetric Activity Kit expressed as nmol/min/mL
|
Three months after starting the intervention in each group
|
Catalase activity
Time Frame: Three months after starting the intervention in each group
|
Enzymatic activity measured by Colorimetric Activity Kit expressed as nmol/min/mL
|
Three months after starting the intervention in each group
|
Lipid profile quantification
Time Frame: Three months after starting the intervention in each group
|
size of cholesterol (main classes and subclasses of lipoproteins) expressed in large, medium and small)
|
Three months after starting the intervention in each group
|
IL-4, IL-6, IL10 and TNFa
Time Frame: Three months after starting the intervention in each group
|
They will be quantified by ELISA technique expressed in pg/ul
|
Three months after starting the intervention in each group
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Nayelli Najera, PhD, Instituto Politecnico Nacional
Publications and helpful links
General Publications
- Goya L, Martin MA, Sarria B, Ramos S, Mateos R, Bravo L. Effect of Cocoa and Its Flavonoids on Biomarkers of Inflammation: Studies of Cell Culture, Animals and Humans. Nutrients. 2016 Apr 9;8(4):212. doi: 10.3390/nu8040212.
- Gutierrez-Salmean G, Meaney E, Lanaspa MA, Cicerchi C, Johnson RJ, Dugar S, Taub P, Ramirez-Sanchez I, Villarreal F, Schreiner G, Ceballos G. A randomized, placebo-controlled, double-blind study on the effects of (-)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects. Int J Cardiol. 2016 Nov 15;223:500-506. doi: 10.1016/j.ijcard.2016.08.158. Epub 2016 Aug 8.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-1-29
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Placebo of Cocoa flavonoids
-
National Polytechnic Institute, MexicoCompletedFrail Elderly Syndrome | Sarcopenia
-
Xinjiang Uygur Pharmaceutical Co., Ltd.Chinese Academy of SciencesUnknown
-
Seoul National University HospitalCompleted
-
Anahuac UniversityInstituto de Seguridad y Servicios Sociales de los Trabajadores del EstadoRecruitingDiabetic NeuropathiesMexico
-
PharmanexUtah State UniversityCompletedHealthyUnited States
-
Universidad Europea de MadridCompletedHealthy AthletesSpain
-
University of SurreyCompletedHealthy Participants | Arterial Stiffness | Vascular Endothelium | Microangiopathy, Diabetic | Polyphenol | Optical TomographyUnited Kingdom
-
Vrije Universiteit BrusselCompletedHypoxia, Altitude
-
University of California, San FranciscoUniversity of California, DavisCompleted